Global Antibody-drug Conjugates for Tumors Supply, Demand and Key Producers, 2026-2032
The global Antibody-drug Conjugates for Tumors market size is expected to reach $ 24582 million by 2032, rising at a market growth of 10.4% CAGR during the forecast period (2026-2032).
Antibody-drug conjugates for tumors, or ADCs, are a class of precision oncology therapeutics that use monoclonal antibodies as targeted carriers linked to highly potent cytotoxic payloads, enabling improved tumor selectivity together with enhanced antitumor activity. Commercial use has already expanded across breast cancer, urothelial cancer, lymphoma, ovarian cancer, and other selected solid and hematologic malignancies. Key upstream inputs mainly include antibody drug substance, cell-culture systems, linker chemistries, toxin payload intermediates, conjugation and purification materials, sterile fill-finish systems, and cold-chain packaging, while downstream customers mainly include multinational pharmaceutical companies, oncology-focused drug developers, hospital oncology departments, cancer centers, and specialty pharmaceutical distribution networks. Supported by the continued growth of leading commercial products such as Enhertu, Trodelvy, Kadcyla, and Polivy in 2025, the tumor ADC market has clearly developed into a high-barrier, high-value segment, with overall industry gross margin typically estimated at around 68%-80%.
At present, the tumor ADC market has moved beyond the early proof-of-concept stage and entered a period characterized by a small number of blockbuster products on the one hand and a steady stream of follow-on entrants on the other. The global commercial landscape is expanding from a limited set of targets and cancer types toward a broader range of solid tumors and hematologic malignancies, and the key question is no longer whether ADCs work, but which platforms can deliver better clinical benefit, more manageable toxicity, and faster label expansion. At the same time, leading companies continue to consolidate their positions through antibody engineering, linker design, payload platforms, and global regulatory capabilities, while later entrants are trying to differentiate themselves through novel targets, bispecific ADCs, new payload classes, and regional licensing strategies.
Looking ahead, the market is likely to maintain strong momentum, but its growth drivers are gradually shifting from reliance on a few flagship products toward a broader combination of label expansion for marketed drugs, continued launches of new products, and deeper use in combination regimens. Validated targets such as HER2, TROP-2, and Nectin-4 still offer room for additional penetration across earlier treatment lines, more tumor types, and perioperative settings. At the same time, emerging targets such as B7-H3, HER3, Claudin, and ROR1, together with payload innovation beyond topoisomerase inhibitor dominance, are pushing the field from competition among a few mature assets toward wider platform-level competition. In this environment, success will increasingly depend on patient selection, toxicity management, CMC scale-up, and global supply stability rather than simply on advancing a candidate into the clinic.
The main growth drivers come first from the oncology market's persistent demand for stronger efficacy and more precise drug delivery. Traditional chemotherapy remains limited by systemic toxicity, while many targeted agents face resistance or narrow patient applicability, so ADCs offer an attractive balance of selective targeting and potent cytotoxic activity. In addition, continuing improvements in linker stability, DAR control, bystander-effect modulation, and highly potent payload design have helped newer ADC generations achieve a better balance between efficacy and safety. Another important driver is the high level of collaboration, licensing, and M&A activity between multinational pharmaceutical companies and innovative biotech firms, which has accelerated platform globalization, clinical development, and commercialization while also concentrating capital and strategic resources in the segment.
The barriers remain substantial. ADC development and manufacturing are far more complex than those of conventional small molecules or standalone antibodies, requiring advanced capabilities across antibodies, linkers, payloads, conjugation processes, analytics, and sterile formulation, which raises both execution risk and production cost. Although clinical potential is strong, safety issues such as hematologic toxicity, interstitial lung disease, ocular toxicity, and neuropathy still represent major constraints for many products as they expand commercially. In addition, as competition intensifies around similar targets, reimbursement scrutiny becomes tougher for high-cost oncology drugs, and regional regulatory and access timelines remain uneven, the industry will increasingly be shaped not only by technology leadership but also by the ability to prove clinical value, control cost, secure supply, and enter global markets effectively.
This report studies the global Antibody-drug Conjugates for Tumors demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Antibody-drug Conjugates for Tumors, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Antibody-drug Conjugates for Tumors that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Antibody-drug Conjugates for Tumors total market, 2021-2032, (USD Million)
Global Antibody-drug Conjugates for Tumors total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Antibody-drug Conjugates for Tumors total market, key domestic companies, and share, (USD Million)
Global Antibody-drug Conjugates for Tumors revenue by player, revenue and market share 2021-2026, (USD Million)
Global Antibody-drug Conjugates for Tumors total market by Type, CAGR, 2021-2032, (USD Million)
Global Antibody-drug Conjugates for Tumors total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Antibody-drug Conjugates for Tumors market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Daiichi Sankyo, Roche, AstraZeneca, Pfizer, Gilead Sciences, Astellas Pharma, AbbVie, Genmab, ADC Therapeutics, RemeGen, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Antibody-drug Conjugates for Tumors market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Antibody-drug Conjugates for Tumors Market, By Region:
1. How big is the global Antibody-drug Conjugates for Tumors market?
2. What is the demand of the global Antibody-drug Conjugates for Tumors market?
3. What is the year over year growth of the global Antibody-drug Conjugates for Tumors market?
4. What is the total value of the global Antibody-drug Conjugates for Tumors market?
5. Who are the Major Players in the global Antibody-drug Conjugates for Tumors market?
6. What are the growth factors driving the market demand?
Antibody-drug conjugates for tumors, or ADCs, are a class of precision oncology therapeutics that use monoclonal antibodies as targeted carriers linked to highly potent cytotoxic payloads, enabling improved tumor selectivity together with enhanced antitumor activity. Commercial use has already expanded across breast cancer, urothelial cancer, lymphoma, ovarian cancer, and other selected solid and hematologic malignancies. Key upstream inputs mainly include antibody drug substance, cell-culture systems, linker chemistries, toxin payload intermediates, conjugation and purification materials, sterile fill-finish systems, and cold-chain packaging, while downstream customers mainly include multinational pharmaceutical companies, oncology-focused drug developers, hospital oncology departments, cancer centers, and specialty pharmaceutical distribution networks. Supported by the continued growth of leading commercial products such as Enhertu, Trodelvy, Kadcyla, and Polivy in 2025, the tumor ADC market has clearly developed into a high-barrier, high-value segment, with overall industry gross margin typically estimated at around 68%-80%.
At present, the tumor ADC market has moved beyond the early proof-of-concept stage and entered a period characterized by a small number of blockbuster products on the one hand and a steady stream of follow-on entrants on the other. The global commercial landscape is expanding from a limited set of targets and cancer types toward a broader range of solid tumors and hematologic malignancies, and the key question is no longer whether ADCs work, but which platforms can deliver better clinical benefit, more manageable toxicity, and faster label expansion. At the same time, leading companies continue to consolidate their positions through antibody engineering, linker design, payload platforms, and global regulatory capabilities, while later entrants are trying to differentiate themselves through novel targets, bispecific ADCs, new payload classes, and regional licensing strategies.
Looking ahead, the market is likely to maintain strong momentum, but its growth drivers are gradually shifting from reliance on a few flagship products toward a broader combination of label expansion for marketed drugs, continued launches of new products, and deeper use in combination regimens. Validated targets such as HER2, TROP-2, and Nectin-4 still offer room for additional penetration across earlier treatment lines, more tumor types, and perioperative settings. At the same time, emerging targets such as B7-H3, HER3, Claudin, and ROR1, together with payload innovation beyond topoisomerase inhibitor dominance, are pushing the field from competition among a few mature assets toward wider platform-level competition. In this environment, success will increasingly depend on patient selection, toxicity management, CMC scale-up, and global supply stability rather than simply on advancing a candidate into the clinic.
The main growth drivers come first from the oncology market's persistent demand for stronger efficacy and more precise drug delivery. Traditional chemotherapy remains limited by systemic toxicity, while many targeted agents face resistance or narrow patient applicability, so ADCs offer an attractive balance of selective targeting and potent cytotoxic activity. In addition, continuing improvements in linker stability, DAR control, bystander-effect modulation, and highly potent payload design have helped newer ADC generations achieve a better balance between efficacy and safety. Another important driver is the high level of collaboration, licensing, and M&A activity between multinational pharmaceutical companies and innovative biotech firms, which has accelerated platform globalization, clinical development, and commercialization while also concentrating capital and strategic resources in the segment.
The barriers remain substantial. ADC development and manufacturing are far more complex than those of conventional small molecules or standalone antibodies, requiring advanced capabilities across antibodies, linkers, payloads, conjugation processes, analytics, and sterile formulation, which raises both execution risk and production cost. Although clinical potential is strong, safety issues such as hematologic toxicity, interstitial lung disease, ocular toxicity, and neuropathy still represent major constraints for many products as they expand commercially. In addition, as competition intensifies around similar targets, reimbursement scrutiny becomes tougher for high-cost oncology drugs, and regional regulatory and access timelines remain uneven, the industry will increasingly be shaped not only by technology leadership but also by the ability to prove clinical value, control cost, secure supply, and enter global markets effectively.
This report studies the global Antibody-drug Conjugates for Tumors demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Antibody-drug Conjugates for Tumors, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Antibody-drug Conjugates for Tumors that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Antibody-drug Conjugates for Tumors total market, 2021-2032, (USD Million)
Global Antibody-drug Conjugates for Tumors total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Antibody-drug Conjugates for Tumors total market, key domestic companies, and share, (USD Million)
Global Antibody-drug Conjugates for Tumors revenue by player, revenue and market share 2021-2026, (USD Million)
Global Antibody-drug Conjugates for Tumors total market by Type, CAGR, 2021-2032, (USD Million)
Global Antibody-drug Conjugates for Tumors total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Antibody-drug Conjugates for Tumors market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Daiichi Sankyo, Roche, AstraZeneca, Pfizer, Gilead Sciences, Astellas Pharma, AbbVie, Genmab, ADC Therapeutics, RemeGen, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Antibody-drug Conjugates for Tumors market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Antibody-drug Conjugates for Tumors Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Topoisomerase Inhibitors
- Tubulin Inhibitors
- DNA-damaging Drugs
- Other
- Intravenous ADCs
- Subcutaneous ADCs
- Other
- Solid Tumors
- Hematologic Malignancies
- Hospitals
- Cancer Centers
- Other
- Daiichi Sankyo
- Roche
- AstraZeneca
- Pfizer
- Gilead Sciences
- Astellas Pharma
- AbbVie
- Genmab
- ADC Therapeutics
- RemeGen
- Kelun-Biotech
- Lepu Biopharma
1. How big is the global Antibody-drug Conjugates for Tumors market?
2. What is the demand of the global Antibody-drug Conjugates for Tumors market?
3. What is the year over year growth of the global Antibody-drug Conjugates for Tumors market?
4. What is the total value of the global Antibody-drug Conjugates for Tumors market?
5. Who are the Major Players in the global Antibody-drug Conjugates for Tumors market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Antibody-drug Conjugates for Tumors Introduction
1.2 World Antibody-drug Conjugates for Tumors Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Antibody-drug Conjugates for Tumors Total Market by Region (by Headquarter Location)
1.3.1 World Antibody-drug Conjugates for Tumors Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Antibody-drug Conjugates for Tumors Revenue (2021-2032)
1.3.3 China Based Company Antibody-drug Conjugates for Tumors Revenue (2021-2032)
1.3.4 Europe Based Company Antibody-drug Conjugates for Tumors Revenue (2021-2032)
1.3.5 Japan Based Company Antibody-drug Conjugates for Tumors Revenue (2021-2032)
1.3.6 South Korea Based Company Antibody-drug Conjugates for Tumors Revenue (2021-2032)
1.3.7 ASEAN Based Company Antibody-drug Conjugates for Tumors Revenue (2021-2032)
1.3.8 India Based Company Antibody-drug Conjugates for Tumors Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Antibody-drug Conjugates for Tumors Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Antibody-drug Conjugates for Tumors Consumption Value (2021-2032)
2.2 World Antibody-drug Conjugates for Tumors Consumption Value by Region
2.2.1 World Antibody-drug Conjugates for Tumors Consumption Value by Region (2021-2026)
2.2.2 World Antibody-drug Conjugates for Tumors Consumption Value Forecast by Region (2027-2032)
2.3 United States Antibody-drug Conjugates for Tumors Consumption Value (2021-2032)
2.4 China Antibody-drug Conjugates for Tumors Consumption Value (2021-2032)
2.5 Europe Antibody-drug Conjugates for Tumors Consumption Value (2021-2032)
2.6 Japan Antibody-drug Conjugates for Tumors Consumption Value (2021-2032)
2.7 South Korea Antibody-drug Conjugates for Tumors Consumption Value (2021-2032)
2.8 ASEAN Antibody-drug Conjugates for Tumors Consumption Value (2021-2032)
2.9 India Antibody-drug Conjugates for Tumors Consumption Value (2021-2032)
3 WORLD ANTIBODY-DRUG CONJUGATES FOR TUMORS COMPANIES COMPETITIVE ANALYSIS
3.1 World Antibody-drug Conjugates for Tumors Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Antibody-drug Conjugates for Tumors Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Antibody-drug Conjugates for Tumors in 2025
3.2.3 Global Concentration Ratios (CR8) for Antibody-drug Conjugates for Tumors in 2025
3.3 Antibody-drug Conjugates for Tumors Company Evaluation Quadrant
3.4 Antibody-drug Conjugates for Tumors Market: Overall Company Footprint Analysis
3.4.1 Antibody-drug Conjugates for Tumors Market: Region Footprint
3.4.2 Antibody-drug Conjugates for Tumors Market: Company Product Type Footprint
3.4.3 Antibody-drug Conjugates for Tumors Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Antibody-drug Conjugates for Tumors Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Antibody-drug Conjugates for Tumors Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Antibody-drug Conjugates for Tumors Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Antibody-drug Conjugates for Tumors Consumption Value Comparison
4.2.1 United States VS China: Antibody-drug Conjugates for Tumors Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Antibody-drug Conjugates for Tumors Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Antibody-drug Conjugates for Tumors Companies and Market Share, 2021-2026
4.3.1 United States Based Antibody-drug Conjugates for Tumors Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Antibody-drug Conjugates for Tumors Revenue, (2021-2026)
4.4 China Based Companies Antibody-drug Conjugates for Tumors Revenue and Market Share, 2021-2026
4.4.1 China Based Antibody-drug Conjugates for Tumors Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Antibody-drug Conjugates for Tumors Revenue, (2021-2026)
4.5 Rest of World Based Antibody-drug Conjugates for Tumors Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Antibody-drug Conjugates for Tumors Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Antibody-drug Conjugates for Tumors Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Antibody-drug Conjugates for Tumors Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Topoisomerase Inhibitors
5.2.2 Tubulin Inhibitors
5.2.3 DNA-damaging Drugs
5.2.4 Other
5.3 Market Segment by Type
5.3.1 World Antibody-drug Conjugates for Tumors Market Size by Type (2021-2026)
5.3.2 World Antibody-drug Conjugates for Tumors Market Size by Type (2027-2032)
5.3.3 World Antibody-drug Conjugates for Tumors Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.1 World Antibody-drug Conjugates for Tumors Market Size Overview by Route of Administration: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Route of Administration
6.2.1 Intravenous ADCs
6.2.2 Subcutaneous ADCs
6.2.3 Other
6.3 Market Segment by Route of Administration
6.3.1 World Antibody-drug Conjugates for Tumors Market Size by Route of Administration (2021-2026)
6.3.2 World Antibody-drug Conjugates for Tumors Market Size by Route of Administration (2027-2032)
6.3.3 World Antibody-drug Conjugates for Tumors Market Size Market Share by Route of Administration (2027-2032)
7 MARKET ANALYSIS BY CANCER
7.1 World Antibody-drug Conjugates for Tumors Market Size Overview by Cancer: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Cancer
7.2.1 Solid Tumors
7.2.2 Hematologic Malignancies
7.3 Market Segment by Cancer
7.3.1 World Antibody-drug Conjugates for Tumors Market Size by Cancer (2021-2026)
7.3.2 World Antibody-drug Conjugates for Tumors Market Size by Cancer (2027-2032)
7.3.3 World Antibody-drug Conjugates for Tumors Market Size Market Share by Cancer (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Antibody-drug Conjugates for Tumors Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Hospitals
8.2.2 Cancer Centers
8.2.3 Other
8.3 Market Segment by Application
8.3.1 World Antibody-drug Conjugates for Tumors Market Size by Application (2021-2026)
8.3.2 World Antibody-drug Conjugates for Tumors Market Size by Application (2027-2032)
8.3.3 World Antibody-drug Conjugates for Tumors Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Daiichi Sankyo
9.1.1 Daiichi Sankyo Details
9.1.2 Daiichi Sankyo Major Business
9.1.3 Daiichi Sankyo Antibody-drug Conjugates for Tumors Product and Services
9.1.4 Daiichi Sankyo Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Daiichi Sankyo Recent Developments/Updates
9.1.6 Daiichi Sankyo Competitive Strengths & Weaknesses
9.2 Roche
9.2.1 Roche Details
9.2.2 Roche Major Business
9.2.3 Roche Antibody-drug Conjugates for Tumors Product and Services
9.2.4 Roche Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Roche Recent Developments/Updates
9.2.6 Roche Competitive Strengths & Weaknesses
9.3 AstraZeneca
9.3.1 AstraZeneca Details
9.3.2 AstraZeneca Major Business
9.3.3 AstraZeneca Antibody-drug Conjugates for Tumors Product and Services
9.3.4 AstraZeneca Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 AstraZeneca Recent Developments/Updates
9.3.6 AstraZeneca Competitive Strengths & Weaknesses
9.4 Pfizer
9.4.1 Pfizer Details
9.4.2 Pfizer Major Business
9.4.3 Pfizer Antibody-drug Conjugates for Tumors Product and Services
9.4.4 Pfizer Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Pfizer Recent Developments/Updates
9.4.6 Pfizer Competitive Strengths & Weaknesses
9.5 Gilead Sciences
9.5.1 Gilead Sciences Details
9.5.2 Gilead Sciences Major Business
9.5.3 Gilead Sciences Antibody-drug Conjugates for Tumors Product and Services
9.5.4 Gilead Sciences Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Gilead Sciences Recent Developments/Updates
9.5.6 Gilead Sciences Competitive Strengths & Weaknesses
9.6 Astellas Pharma
9.6.1 Astellas Pharma Details
9.6.2 Astellas Pharma Major Business
9.6.3 Astellas Pharma Antibody-drug Conjugates for Tumors Product and Services
9.6.4 Astellas Pharma Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Astellas Pharma Recent Developments/Updates
9.6.6 Astellas Pharma Competitive Strengths & Weaknesses
9.7 AbbVie
9.7.1 AbbVie Details
9.7.2 AbbVie Major Business
9.7.3 AbbVie Antibody-drug Conjugates for Tumors Product and Services
9.7.4 AbbVie Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 AbbVie Recent Developments/Updates
9.7.6 AbbVie Competitive Strengths & Weaknesses
9.8 Genmab
9.8.1 Genmab Details
9.8.2 Genmab Major Business
9.8.3 Genmab Antibody-drug Conjugates for Tumors Product and Services
9.8.4 Genmab Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Genmab Recent Developments/Updates
9.8.6 Genmab Competitive Strengths & Weaknesses
9.9 ADC Therapeutics
9.9.1 ADC Therapeutics Details
9.9.2 ADC Therapeutics Major Business
9.9.3 ADC Therapeutics Antibody-drug Conjugates for Tumors Product and Services
9.9.4 ADC Therapeutics Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 ADC Therapeutics Recent Developments/Updates
9.9.6 ADC Therapeutics Competitive Strengths & Weaknesses
9.10 RemeGen
9.10.1 RemeGen Details
9.10.2 RemeGen Major Business
9.10.3 RemeGen Antibody-drug Conjugates for Tumors Product and Services
9.10.4 RemeGen Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 RemeGen Recent Developments/Updates
9.10.6 RemeGen Competitive Strengths & Weaknesses
9.11 Kelun-Biotech
9.11.1 Kelun-Biotech Details
9.11.2 Kelun-Biotech Major Business
9.11.3 Kelun-Biotech Antibody-drug Conjugates for Tumors Product and Services
9.11.4 Kelun-Biotech Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 Kelun-Biotech Recent Developments/Updates
9.11.6 Kelun-Biotech Competitive Strengths & Weaknesses
9.12 Lepu Biopharma
9.12.1 Lepu Biopharma Details
9.12.2 Lepu Biopharma Major Business
9.12.3 Lepu Biopharma Antibody-drug Conjugates for Tumors Product and Services
9.12.4 Lepu Biopharma Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 Lepu Biopharma Recent Developments/Updates
9.12.6 Lepu Biopharma Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Antibody-drug Conjugates for Tumors Industry Chain
10.2 Antibody-drug Conjugates for Tumors Upstream Analysis
10.3 Antibody-drug Conjugates for Tumors Midstream Analysis
10.4 Antibody-drug Conjugates for Tumors Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Antibody-drug Conjugates for Tumors Introduction
1.2 World Antibody-drug Conjugates for Tumors Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Antibody-drug Conjugates for Tumors Total Market by Region (by Headquarter Location)
1.3.1 World Antibody-drug Conjugates for Tumors Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Antibody-drug Conjugates for Tumors Revenue (2021-2032)
1.3.3 China Based Company Antibody-drug Conjugates for Tumors Revenue (2021-2032)
1.3.4 Europe Based Company Antibody-drug Conjugates for Tumors Revenue (2021-2032)
1.3.5 Japan Based Company Antibody-drug Conjugates for Tumors Revenue (2021-2032)
1.3.6 South Korea Based Company Antibody-drug Conjugates for Tumors Revenue (2021-2032)
1.3.7 ASEAN Based Company Antibody-drug Conjugates for Tumors Revenue (2021-2032)
1.3.8 India Based Company Antibody-drug Conjugates for Tumors Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Antibody-drug Conjugates for Tumors Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Antibody-drug Conjugates for Tumors Consumption Value (2021-2032)
2.2 World Antibody-drug Conjugates for Tumors Consumption Value by Region
2.2.1 World Antibody-drug Conjugates for Tumors Consumption Value by Region (2021-2026)
2.2.2 World Antibody-drug Conjugates for Tumors Consumption Value Forecast by Region (2027-2032)
2.3 United States Antibody-drug Conjugates for Tumors Consumption Value (2021-2032)
2.4 China Antibody-drug Conjugates for Tumors Consumption Value (2021-2032)
2.5 Europe Antibody-drug Conjugates for Tumors Consumption Value (2021-2032)
2.6 Japan Antibody-drug Conjugates for Tumors Consumption Value (2021-2032)
2.7 South Korea Antibody-drug Conjugates for Tumors Consumption Value (2021-2032)
2.8 ASEAN Antibody-drug Conjugates for Tumors Consumption Value (2021-2032)
2.9 India Antibody-drug Conjugates for Tumors Consumption Value (2021-2032)
3 WORLD ANTIBODY-DRUG CONJUGATES FOR TUMORS COMPANIES COMPETITIVE ANALYSIS
3.1 World Antibody-drug Conjugates for Tumors Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Antibody-drug Conjugates for Tumors Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Antibody-drug Conjugates for Tumors in 2025
3.2.3 Global Concentration Ratios (CR8) for Antibody-drug Conjugates for Tumors in 2025
3.3 Antibody-drug Conjugates for Tumors Company Evaluation Quadrant
3.4 Antibody-drug Conjugates for Tumors Market: Overall Company Footprint Analysis
3.4.1 Antibody-drug Conjugates for Tumors Market: Region Footprint
3.4.2 Antibody-drug Conjugates for Tumors Market: Company Product Type Footprint
3.4.3 Antibody-drug Conjugates for Tumors Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Antibody-drug Conjugates for Tumors Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Antibody-drug Conjugates for Tumors Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Antibody-drug Conjugates for Tumors Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Antibody-drug Conjugates for Tumors Consumption Value Comparison
4.2.1 United States VS China: Antibody-drug Conjugates for Tumors Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Antibody-drug Conjugates for Tumors Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Antibody-drug Conjugates for Tumors Companies and Market Share, 2021-2026
4.3.1 United States Based Antibody-drug Conjugates for Tumors Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Antibody-drug Conjugates for Tumors Revenue, (2021-2026)
4.4 China Based Companies Antibody-drug Conjugates for Tumors Revenue and Market Share, 2021-2026
4.4.1 China Based Antibody-drug Conjugates for Tumors Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Antibody-drug Conjugates for Tumors Revenue, (2021-2026)
4.5 Rest of World Based Antibody-drug Conjugates for Tumors Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Antibody-drug Conjugates for Tumors Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Antibody-drug Conjugates for Tumors Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Antibody-drug Conjugates for Tumors Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Topoisomerase Inhibitors
5.2.2 Tubulin Inhibitors
5.2.3 DNA-damaging Drugs
5.2.4 Other
5.3 Market Segment by Type
5.3.1 World Antibody-drug Conjugates for Tumors Market Size by Type (2021-2026)
5.3.2 World Antibody-drug Conjugates for Tumors Market Size by Type (2027-2032)
5.3.3 World Antibody-drug Conjugates for Tumors Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.1 World Antibody-drug Conjugates for Tumors Market Size Overview by Route of Administration: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Route of Administration
6.2.1 Intravenous ADCs
6.2.2 Subcutaneous ADCs
6.2.3 Other
6.3 Market Segment by Route of Administration
6.3.1 World Antibody-drug Conjugates for Tumors Market Size by Route of Administration (2021-2026)
6.3.2 World Antibody-drug Conjugates for Tumors Market Size by Route of Administration (2027-2032)
6.3.3 World Antibody-drug Conjugates for Tumors Market Size Market Share by Route of Administration (2027-2032)
7 MARKET ANALYSIS BY CANCER
7.1 World Antibody-drug Conjugates for Tumors Market Size Overview by Cancer: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Cancer
7.2.1 Solid Tumors
7.2.2 Hematologic Malignancies
7.3 Market Segment by Cancer
7.3.1 World Antibody-drug Conjugates for Tumors Market Size by Cancer (2021-2026)
7.3.2 World Antibody-drug Conjugates for Tumors Market Size by Cancer (2027-2032)
7.3.3 World Antibody-drug Conjugates for Tumors Market Size Market Share by Cancer (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Antibody-drug Conjugates for Tumors Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Hospitals
8.2.2 Cancer Centers
8.2.3 Other
8.3 Market Segment by Application
8.3.1 World Antibody-drug Conjugates for Tumors Market Size by Application (2021-2026)
8.3.2 World Antibody-drug Conjugates for Tumors Market Size by Application (2027-2032)
8.3.3 World Antibody-drug Conjugates for Tumors Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Daiichi Sankyo
9.1.1 Daiichi Sankyo Details
9.1.2 Daiichi Sankyo Major Business
9.1.3 Daiichi Sankyo Antibody-drug Conjugates for Tumors Product and Services
9.1.4 Daiichi Sankyo Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Daiichi Sankyo Recent Developments/Updates
9.1.6 Daiichi Sankyo Competitive Strengths & Weaknesses
9.2 Roche
9.2.1 Roche Details
9.2.2 Roche Major Business
9.2.3 Roche Antibody-drug Conjugates for Tumors Product and Services
9.2.4 Roche Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Roche Recent Developments/Updates
9.2.6 Roche Competitive Strengths & Weaknesses
9.3 AstraZeneca
9.3.1 AstraZeneca Details
9.3.2 AstraZeneca Major Business
9.3.3 AstraZeneca Antibody-drug Conjugates for Tumors Product and Services
9.3.4 AstraZeneca Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 AstraZeneca Recent Developments/Updates
9.3.6 AstraZeneca Competitive Strengths & Weaknesses
9.4 Pfizer
9.4.1 Pfizer Details
9.4.2 Pfizer Major Business
9.4.3 Pfizer Antibody-drug Conjugates for Tumors Product and Services
9.4.4 Pfizer Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Pfizer Recent Developments/Updates
9.4.6 Pfizer Competitive Strengths & Weaknesses
9.5 Gilead Sciences
9.5.1 Gilead Sciences Details
9.5.2 Gilead Sciences Major Business
9.5.3 Gilead Sciences Antibody-drug Conjugates for Tumors Product and Services
9.5.4 Gilead Sciences Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Gilead Sciences Recent Developments/Updates
9.5.6 Gilead Sciences Competitive Strengths & Weaknesses
9.6 Astellas Pharma
9.6.1 Astellas Pharma Details
9.6.2 Astellas Pharma Major Business
9.6.3 Astellas Pharma Antibody-drug Conjugates for Tumors Product and Services
9.6.4 Astellas Pharma Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Astellas Pharma Recent Developments/Updates
9.6.6 Astellas Pharma Competitive Strengths & Weaknesses
9.7 AbbVie
9.7.1 AbbVie Details
9.7.2 AbbVie Major Business
9.7.3 AbbVie Antibody-drug Conjugates for Tumors Product and Services
9.7.4 AbbVie Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 AbbVie Recent Developments/Updates
9.7.6 AbbVie Competitive Strengths & Weaknesses
9.8 Genmab
9.8.1 Genmab Details
9.8.2 Genmab Major Business
9.8.3 Genmab Antibody-drug Conjugates for Tumors Product and Services
9.8.4 Genmab Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Genmab Recent Developments/Updates
9.8.6 Genmab Competitive Strengths & Weaknesses
9.9 ADC Therapeutics
9.9.1 ADC Therapeutics Details
9.9.2 ADC Therapeutics Major Business
9.9.3 ADC Therapeutics Antibody-drug Conjugates for Tumors Product and Services
9.9.4 ADC Therapeutics Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 ADC Therapeutics Recent Developments/Updates
9.9.6 ADC Therapeutics Competitive Strengths & Weaknesses
9.10 RemeGen
9.10.1 RemeGen Details
9.10.2 RemeGen Major Business
9.10.3 RemeGen Antibody-drug Conjugates for Tumors Product and Services
9.10.4 RemeGen Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 RemeGen Recent Developments/Updates
9.10.6 RemeGen Competitive Strengths & Weaknesses
9.11 Kelun-Biotech
9.11.1 Kelun-Biotech Details
9.11.2 Kelun-Biotech Major Business
9.11.3 Kelun-Biotech Antibody-drug Conjugates for Tumors Product and Services
9.11.4 Kelun-Biotech Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 Kelun-Biotech Recent Developments/Updates
9.11.6 Kelun-Biotech Competitive Strengths & Weaknesses
9.12 Lepu Biopharma
9.12.1 Lepu Biopharma Details
9.12.2 Lepu Biopharma Major Business
9.12.3 Lepu Biopharma Antibody-drug Conjugates for Tumors Product and Services
9.12.4 Lepu Biopharma Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 Lepu Biopharma Recent Developments/Updates
9.12.6 Lepu Biopharma Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Antibody-drug Conjugates for Tumors Industry Chain
10.2 Antibody-drug Conjugates for Tumors Upstream Analysis
10.3 Antibody-drug Conjugates for Tumors Midstream Analysis
10.4 Antibody-drug Conjugates for Tumors Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Antibody-drug Conjugates for Tumors Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Antibody-drug Conjugates for Tumors Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Antibody-drug Conjugates for Tumors Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Antibody-drug Conjugates for Tumors Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Antibody-drug Conjugates for Tumors Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Antibody-drug Conjugates for Tumors Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Antibody-drug Conjugates for Tumors Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Antibody-drug Conjugates for Tumors Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Antibody-drug Conjugates for Tumors Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Antibody-drug Conjugates for Tumors Players in 2025
Table 12. World Antibody-drug Conjugates for Tumors Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Antibody-drug Conjugates for Tumors Company Evaluation Quadrant
Table 14. Head Office of Key Antibody-drug Conjugates for Tumors Players
Table 15. Antibody-drug Conjugates for Tumors Market: Company Product Type Footprint
Table 16. Antibody-drug Conjugates for Tumors Market: Company Product Application Footprint
Table 17. Antibody-drug Conjugates for Tumors Mergers & Acquisitions Activity
Table 18. United States VS China Antibody-drug Conjugates for Tumors Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Antibody-drug Conjugates for Tumors Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Antibody-drug Conjugates for Tumors Companies, Headquarters (States, Country)
Table 21. United States Based Companies Antibody-drug Conjugates for Tumors Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Antibody-drug Conjugates for Tumors Revenue Market Share (2021-2026)
Table 23. China Based Antibody-drug Conjugates for Tumors Companies, Headquarters (Province, Country)
Table 24. China Based Companies Antibody-drug Conjugates for Tumors Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Antibody-drug Conjugates for Tumors Revenue Market Share (2021-2026)
Table 26. Rest of World Based Antibody-drug Conjugates for Tumors Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Antibody-drug Conjugates for Tumors Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Antibody-drug Conjugates for Tumors Revenue Market Share (2021-2026)
Table 29. World Antibody-drug Conjugates for Tumors Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Antibody-drug Conjugates for Tumors Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Antibody-drug Conjugates for Tumors Market Size by Type (2027-2032) & (USD Million)
Table 32. World Antibody-drug Conjugates for Tumors Market Size by Route of Administration, (USD Million), 2021 & 2025 & 2032
Table 33. World Antibody-drug Conjugates for Tumors Market Size Value by Route of Administration (2021-2026) & (USD Million)
Table 34. World Antibody-drug Conjugates for Tumors Market Size by Route of Administration (2027-2032) & (USD Million)
Table 35. World Antibody-drug Conjugates for Tumors Market Size by Cancer, (USD Million), 2021 & 2025 & 2032
Table 36. World Antibody-drug Conjugates for Tumors Market Size Value by Cancer (2021-2026) & (USD Million)
Table 37. World Antibody-drug Conjugates for Tumors Market Size by Cancer (2027-2032) & (USD Million)
Table 38. World Antibody-drug Conjugates for Tumors Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Antibody-drug Conjugates for Tumors Market Size by Application (2021-2026) & (USD Million)
Table 40. World Antibody-drug Conjugates for Tumors Market Size by Application (2027-2032) & (USD Million)
Table 41. Daiichi Sankyo Basic Information, Manufacturing Base and Competitors
Table 42. Daiichi Sankyo Major Business
Table 43. Daiichi Sankyo Antibody-drug Conjugates for Tumors Product and Services
Table 44. Daiichi Sankyo Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Daiichi Sankyo Recent Developments/Updates
Table 46. Daiichi Sankyo Competitive Strengths & Weaknesses
Table 47. Roche Basic Information, Manufacturing Base and Competitors
Table 48. Roche Major Business
Table 49. Roche Antibody-drug Conjugates for Tumors Product and Services
Table 50. Roche Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Roche Recent Developments/Updates
Table 52. Roche Competitive Strengths & Weaknesses
Table 53. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 54. AstraZeneca Major Business
Table 55. AstraZeneca Antibody-drug Conjugates for Tumors Product and Services
Table 56. AstraZeneca Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. AstraZeneca Recent Developments/Updates
Table 58. AstraZeneca Competitive Strengths & Weaknesses
Table 59. Pfizer Basic Information, Manufacturing Base and Competitors
Table 60. Pfizer Major Business
Table 61. Pfizer Antibody-drug Conjugates for Tumors Product and Services
Table 62. Pfizer Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Pfizer Recent Developments/Updates
Table 64. Pfizer Competitive Strengths & Weaknesses
Table 65. Gilead Sciences Basic Information, Manufacturing Base and Competitors
Table 66. Gilead Sciences Major Business
Table 67. Gilead Sciences Antibody-drug Conjugates for Tumors Product and Services
Table 68. Gilead Sciences Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Gilead Sciences Recent Developments/Updates
Table 70. Gilead Sciences Competitive Strengths & Weaknesses
Table 71. Astellas Pharma Basic Information, Manufacturing Base and Competitors
Table 72. Astellas Pharma Major Business
Table 73. Astellas Pharma Antibody-drug Conjugates for Tumors Product and Services
Table 74. Astellas Pharma Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Astellas Pharma Recent Developments/Updates
Table 76. Astellas Pharma Competitive Strengths & Weaknesses
Table 77. AbbVie Basic Information, Manufacturing Base and Competitors
Table 78. AbbVie Major Business
Table 79. AbbVie Antibody-drug Conjugates for Tumors Product and Services
Table 80. AbbVie Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. AbbVie Recent Developments/Updates
Table 82. AbbVie Competitive Strengths & Weaknesses
Table 83. Genmab Basic Information, Manufacturing Base and Competitors
Table 84. Genmab Major Business
Table 85. Genmab Antibody-drug Conjugates for Tumors Product and Services
Table 86. Genmab Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Genmab Recent Developments/Updates
Table 88. Genmab Competitive Strengths & Weaknesses
Table 89. ADC Therapeutics Basic Information, Manufacturing Base and Competitors
Table 90. ADC Therapeutics Major Business
Table 91. ADC Therapeutics Antibody-drug Conjugates for Tumors Product and Services
Table 92. ADC Therapeutics Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. ADC Therapeutics Recent Developments/Updates
Table 94. ADC Therapeutics Competitive Strengths & Weaknesses
Table 95. RemeGen Basic Information, Manufacturing Base and Competitors
Table 96. RemeGen Major Business
Table 97. RemeGen Antibody-drug Conjugates for Tumors Product and Services
Table 98. RemeGen Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. RemeGen Recent Developments/Updates
Table 100. RemeGen Competitive Strengths & Weaknesses
Table 101. Kelun-Biotech Basic Information, Manufacturing Base and Competitors
Table 102. Kelun-Biotech Major Business
Table 103. Kelun-Biotech Antibody-drug Conjugates for Tumors Product and Services
Table 104. Kelun-Biotech Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. Kelun-Biotech Recent Developments/Updates
Table 106. Kelun-Biotech Competitive Strengths & Weaknesses
Table 107. Lepu Biopharma Basic Information, Manufacturing Base and Competitors
Table 108. Lepu Biopharma Major Business
Table 109. Lepu Biopharma Antibody-drug Conjugates for Tumors Product and Services
Table 110. Lepu Biopharma Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. Lepu Biopharma Recent Developments/Updates
Table 112. Lepu Biopharma Competitive Strengths & Weaknesses
Table 113. Global Key Players of Antibody-drug Conjugates for Tumors Upstream (Raw Materials)
Table 114. Global Antibody-drug Conjugates for Tumors Typical Customers
Table 1. World Antibody-drug Conjugates for Tumors Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Antibody-drug Conjugates for Tumors Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Antibody-drug Conjugates for Tumors Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Antibody-drug Conjugates for Tumors Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Antibody-drug Conjugates for Tumors Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Antibody-drug Conjugates for Tumors Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Antibody-drug Conjugates for Tumors Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Antibody-drug Conjugates for Tumors Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Antibody-drug Conjugates for Tumors Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Antibody-drug Conjugates for Tumors Players in 2025
Table 12. World Antibody-drug Conjugates for Tumors Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Antibody-drug Conjugates for Tumors Company Evaluation Quadrant
Table 14. Head Office of Key Antibody-drug Conjugates for Tumors Players
Table 15. Antibody-drug Conjugates for Tumors Market: Company Product Type Footprint
Table 16. Antibody-drug Conjugates for Tumors Market: Company Product Application Footprint
Table 17. Antibody-drug Conjugates for Tumors Mergers & Acquisitions Activity
Table 18. United States VS China Antibody-drug Conjugates for Tumors Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Antibody-drug Conjugates for Tumors Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Antibody-drug Conjugates for Tumors Companies, Headquarters (States, Country)
Table 21. United States Based Companies Antibody-drug Conjugates for Tumors Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Antibody-drug Conjugates for Tumors Revenue Market Share (2021-2026)
Table 23. China Based Antibody-drug Conjugates for Tumors Companies, Headquarters (Province, Country)
Table 24. China Based Companies Antibody-drug Conjugates for Tumors Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Antibody-drug Conjugates for Tumors Revenue Market Share (2021-2026)
Table 26. Rest of World Based Antibody-drug Conjugates for Tumors Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Antibody-drug Conjugates for Tumors Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Antibody-drug Conjugates for Tumors Revenue Market Share (2021-2026)
Table 29. World Antibody-drug Conjugates for Tumors Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Antibody-drug Conjugates for Tumors Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Antibody-drug Conjugates for Tumors Market Size by Type (2027-2032) & (USD Million)
Table 32. World Antibody-drug Conjugates for Tumors Market Size by Route of Administration, (USD Million), 2021 & 2025 & 2032
Table 33. World Antibody-drug Conjugates for Tumors Market Size Value by Route of Administration (2021-2026) & (USD Million)
Table 34. World Antibody-drug Conjugates for Tumors Market Size by Route of Administration (2027-2032) & (USD Million)
Table 35. World Antibody-drug Conjugates for Tumors Market Size by Cancer, (USD Million), 2021 & 2025 & 2032
Table 36. World Antibody-drug Conjugates for Tumors Market Size Value by Cancer (2021-2026) & (USD Million)
Table 37. World Antibody-drug Conjugates for Tumors Market Size by Cancer (2027-2032) & (USD Million)
Table 38. World Antibody-drug Conjugates for Tumors Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Antibody-drug Conjugates for Tumors Market Size by Application (2021-2026) & (USD Million)
Table 40. World Antibody-drug Conjugates for Tumors Market Size by Application (2027-2032) & (USD Million)
Table 41. Daiichi Sankyo Basic Information, Manufacturing Base and Competitors
Table 42. Daiichi Sankyo Major Business
Table 43. Daiichi Sankyo Antibody-drug Conjugates for Tumors Product and Services
Table 44. Daiichi Sankyo Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Daiichi Sankyo Recent Developments/Updates
Table 46. Daiichi Sankyo Competitive Strengths & Weaknesses
Table 47. Roche Basic Information, Manufacturing Base and Competitors
Table 48. Roche Major Business
Table 49. Roche Antibody-drug Conjugates for Tumors Product and Services
Table 50. Roche Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Roche Recent Developments/Updates
Table 52. Roche Competitive Strengths & Weaknesses
Table 53. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 54. AstraZeneca Major Business
Table 55. AstraZeneca Antibody-drug Conjugates for Tumors Product and Services
Table 56. AstraZeneca Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. AstraZeneca Recent Developments/Updates
Table 58. AstraZeneca Competitive Strengths & Weaknesses
Table 59. Pfizer Basic Information, Manufacturing Base and Competitors
Table 60. Pfizer Major Business
Table 61. Pfizer Antibody-drug Conjugates for Tumors Product and Services
Table 62. Pfizer Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Pfizer Recent Developments/Updates
Table 64. Pfizer Competitive Strengths & Weaknesses
Table 65. Gilead Sciences Basic Information, Manufacturing Base and Competitors
Table 66. Gilead Sciences Major Business
Table 67. Gilead Sciences Antibody-drug Conjugates for Tumors Product and Services
Table 68. Gilead Sciences Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Gilead Sciences Recent Developments/Updates
Table 70. Gilead Sciences Competitive Strengths & Weaknesses
Table 71. Astellas Pharma Basic Information, Manufacturing Base and Competitors
Table 72. Astellas Pharma Major Business
Table 73. Astellas Pharma Antibody-drug Conjugates for Tumors Product and Services
Table 74. Astellas Pharma Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Astellas Pharma Recent Developments/Updates
Table 76. Astellas Pharma Competitive Strengths & Weaknesses
Table 77. AbbVie Basic Information, Manufacturing Base and Competitors
Table 78. AbbVie Major Business
Table 79. AbbVie Antibody-drug Conjugates for Tumors Product and Services
Table 80. AbbVie Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. AbbVie Recent Developments/Updates
Table 82. AbbVie Competitive Strengths & Weaknesses
Table 83. Genmab Basic Information, Manufacturing Base and Competitors
Table 84. Genmab Major Business
Table 85. Genmab Antibody-drug Conjugates for Tumors Product and Services
Table 86. Genmab Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Genmab Recent Developments/Updates
Table 88. Genmab Competitive Strengths & Weaknesses
Table 89. ADC Therapeutics Basic Information, Manufacturing Base and Competitors
Table 90. ADC Therapeutics Major Business
Table 91. ADC Therapeutics Antibody-drug Conjugates for Tumors Product and Services
Table 92. ADC Therapeutics Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. ADC Therapeutics Recent Developments/Updates
Table 94. ADC Therapeutics Competitive Strengths & Weaknesses
Table 95. RemeGen Basic Information, Manufacturing Base and Competitors
Table 96. RemeGen Major Business
Table 97. RemeGen Antibody-drug Conjugates for Tumors Product and Services
Table 98. RemeGen Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. RemeGen Recent Developments/Updates
Table 100. RemeGen Competitive Strengths & Weaknesses
Table 101. Kelun-Biotech Basic Information, Manufacturing Base and Competitors
Table 102. Kelun-Biotech Major Business
Table 103. Kelun-Biotech Antibody-drug Conjugates for Tumors Product and Services
Table 104. Kelun-Biotech Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. Kelun-Biotech Recent Developments/Updates
Table 106. Kelun-Biotech Competitive Strengths & Weaknesses
Table 107. Lepu Biopharma Basic Information, Manufacturing Base and Competitors
Table 108. Lepu Biopharma Major Business
Table 109. Lepu Biopharma Antibody-drug Conjugates for Tumors Product and Services
Table 110. Lepu Biopharma Antibody-drug Conjugates for Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. Lepu Biopharma Recent Developments/Updates
Table 112. Lepu Biopharma Competitive Strengths & Weaknesses
Table 113. Global Key Players of Antibody-drug Conjugates for Tumors Upstream (Raw Materials)
Table 114. Global Antibody-drug Conjugates for Tumors Typical Customers
LIST OF FIGURES
Figure 1. Antibody-drug Conjugates for Tumors Picture
Figure 2. World Antibody-drug Conjugates for Tumors Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Antibody-drug Conjugates for Tumors Total Revenue (2021-2032) & (USD Million)
Figure 4. World Antibody-drug Conjugates for Tumors Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Antibody-drug Conjugates for Tumors Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (USD Million)
Figure 13. Antibody-drug Conjugates for Tumors Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Antibody-drug Conjugates for Tumors Consumption Value (2021-2032) & (USD Million)
Figure 16. World Antibody-drug Conjugates for Tumors Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Antibody-drug Conjugates for Tumors Consumption Value (2021-2032) & (USD Million)
Figure 18. China Antibody-drug Conjugates for Tumors Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Antibody-drug Conjugates for Tumors Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Antibody-drug Conjugates for Tumors Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Antibody-drug Conjugates for Tumors Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Antibody-drug Conjugates for Tumors Consumption Value (2021-2032) & (USD Million)
Figure 23. India Antibody-drug Conjugates for Tumors Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Antibody-drug Conjugates for Tumors by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Antibody-drug Conjugates for Tumors Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Antibody-drug Conjugates for Tumors Markets in 2025
Figure 27. United States VS China: Antibody-drug Conjugates for Tumors Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Antibody-drug Conjugates for Tumors Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Antibody-drug Conjugates for Tumors Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Antibody-drug Conjugates for Tumors Market Size Market Share by Type in 2025
Figure 31. Topoisomerase Inhibitors
Figure 32. Tubulin Inhibitors
Figure 33. DNA-damaging Drugs
Figure 34. Other
Figure 35. World Antibody-drug Conjugates for Tumors Market Size Market Share by Type (2021-2032)
Figure 36. World Antibody-drug Conjugates for Tumors Market Size by Route of Administration, (USD Million), 2021 & 2025 & 2032
Figure 37. World Antibody-drug Conjugates for Tumors Market Size Market Share by Route of Administration in 2025
Figure 38. Intravenous ADCs
Figure 39. Subcutaneous ADCs
Figure 40. Other
Figure 41. World Antibody-drug Conjugates for Tumors Market Size Market Share by Route of Administration (2021-2032)
Figure 42. World Antibody-drug Conjugates for Tumors Market Size by Cancer, (USD Million), 2021 & 2025 & 2032
Figure 43. World Antibody-drug Conjugates for Tumors Market Size Market Share by Cancer in 2025
Figure 44. Solid Tumors
Figure 45. Hematologic Malignancies
Figure 46. World Antibody-drug Conjugates for Tumors Market Size Market Share by Cancer (2021-2032)
Figure 47. World Antibody-drug Conjugates for Tumors Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 48. World Antibody-drug Conjugates for Tumors Market Size Market Share by Application in 2025
Figure 49. Hospitals
Figure 50. Cancer Centers
Figure 51. Other
Figure 52. World Antibody-drug Conjugates for Tumors Market Size Market Share by Application (2021-2032)
Figure 53. Antibody-drug Conjugates for Tumors Industrial Chain
Figure 54. Methodology
Figure 55. Research Process and Data Source
Figure 1. Antibody-drug Conjugates for Tumors Picture
Figure 2. World Antibody-drug Conjugates for Tumors Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Antibody-drug Conjugates for Tumors Total Revenue (2021-2032) & (USD Million)
Figure 4. World Antibody-drug Conjugates for Tumors Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Antibody-drug Conjugates for Tumors Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (USD Million)
Figure 13. Antibody-drug Conjugates for Tumors Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Antibody-drug Conjugates for Tumors Consumption Value (2021-2032) & (USD Million)
Figure 16. World Antibody-drug Conjugates for Tumors Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Antibody-drug Conjugates for Tumors Consumption Value (2021-2032) & (USD Million)
Figure 18. China Antibody-drug Conjugates for Tumors Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Antibody-drug Conjugates for Tumors Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Antibody-drug Conjugates for Tumors Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Antibody-drug Conjugates for Tumors Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Antibody-drug Conjugates for Tumors Consumption Value (2021-2032) & (USD Million)
Figure 23. India Antibody-drug Conjugates for Tumors Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Antibody-drug Conjugates for Tumors by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Antibody-drug Conjugates for Tumors Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Antibody-drug Conjugates for Tumors Markets in 2025
Figure 27. United States VS China: Antibody-drug Conjugates for Tumors Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Antibody-drug Conjugates for Tumors Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Antibody-drug Conjugates for Tumors Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Antibody-drug Conjugates for Tumors Market Size Market Share by Type in 2025
Figure 31. Topoisomerase Inhibitors
Figure 32. Tubulin Inhibitors
Figure 33. DNA-damaging Drugs
Figure 34. Other
Figure 35. World Antibody-drug Conjugates for Tumors Market Size Market Share by Type (2021-2032)
Figure 36. World Antibody-drug Conjugates for Tumors Market Size by Route of Administration, (USD Million), 2021 & 2025 & 2032
Figure 37. World Antibody-drug Conjugates for Tumors Market Size Market Share by Route of Administration in 2025
Figure 38. Intravenous ADCs
Figure 39. Subcutaneous ADCs
Figure 40. Other
Figure 41. World Antibody-drug Conjugates for Tumors Market Size Market Share by Route of Administration (2021-2032)
Figure 42. World Antibody-drug Conjugates for Tumors Market Size by Cancer, (USD Million), 2021 & 2025 & 2032
Figure 43. World Antibody-drug Conjugates for Tumors Market Size Market Share by Cancer in 2025
Figure 44. Solid Tumors
Figure 45. Hematologic Malignancies
Figure 46. World Antibody-drug Conjugates for Tumors Market Size Market Share by Cancer (2021-2032)
Figure 47. World Antibody-drug Conjugates for Tumors Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 48. World Antibody-drug Conjugates for Tumors Market Size Market Share by Application in 2025
Figure 49. Hospitals
Figure 50. Cancer Centers
Figure 51. Other
Figure 52. World Antibody-drug Conjugates for Tumors Market Size Market Share by Application (2021-2032)
Figure 53. Antibody-drug Conjugates for Tumors Industrial Chain
Figure 54. Methodology
Figure 55. Research Process and Data Source
